21 Feb 2023 Bionest Alzheimer’s Disease Update Part 1: Lecanemab Provides New Support for the Amyloid Hypothesis What will the recent accelerated approval of anti-amyloid lecanemab mean for Alzheimers patients, and will it overcome stringent CMS reimbursement policies?
6 Feb 2023 Bionest Innovation in Generics: New Oral Drug Delivery System for IBD and Beyond Novel drug delivery systems offer a valuable approach to differentiating drugs, especially those competing within a generic market